Google+

Young Blood the Key To Stop Alzheimer’s?

The company behind a Phase 2 trial of its proprietary young plasma protein formulation says it...
The company behind a Phase 2 trial of its proprietary young plasma protein formulation says it can potentially slow, or even stop, cognitive decline associated with Alzheimer’s disease(Credit: albund/Depositphotos)

Alkahest, a California-based biotech start-up, has just revealed some compelling early results from an ongoing Phase 2 trial into the efficacy of its novel formulation of plasma proteins derived from young blood, developed to slow, or even stop, the cognitive decline associated with Alzheimer’s disease. read more